

# Angiotensin Receptor Blockers (ARBs) Global Market 2024 To Reach \$10.28 Billion By 2028 At Rate Of 4.5%

*Angiotensin Receptor Blockers (ARBs) Global Market Size, Insights Forecast, Growth, Trends 2024-2033*

LONDON, GREATER LONDON, UNITED KINGDOM, October 1, 2024

/EINPresswire.com/ -- The angiotensin receptor blockers (ARBs) market has experienced robust growth in recent

years, expanding from \$8.26 billion in 2023 to \$8.62 billion in 2024 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to hypertension epidemic, clinical efficacy, cardiovascular disease burden, renal protection, clinical guidelines, ARBs as first-line treatment, cost-effectiveness.



You Can Now Pre Order  
Your Report To Get A Swift  
Deliver With All Your Needs  
"

*The Business Research  
Company*

What Is The Estimated Market Size Of The Global Angiotensin Receptor Blockers (ARBs) Market And Its Annual Growth Rate?

The angiotensin receptor blockers (ARBs) market is projected to continue its strong growth, reaching \$10.28 billion in 2028 at a compound annual growth rate (CAGR) of 4.5%. The growth in the forecast period can be attributed to precision medicine approaches, focus on

combination therapies, global expansion of market, biomarker-based treatment strategies, government initiatives, increased awareness of hypertension.

Explore Comprehensive Insights Into The Global Angiotensin Receptor Blockers (ARBs) Market With A Detailed Sample Report:

[https://www.thebusinessresearchcompany.com/sample\\_request?id=8943&type=smp](https://www.thebusinessresearchcompany.com/sample_request?id=8943&type=smp)

Growth Driver Of The Angiotensin Receptor Blockers (ARBs) Market

The increasing chronic kidney diseases is expected to propel the growth of the angiotensin



The Business  
Research Company

Angiotensin Receptor Blockers (ARBs) Global Market Size, Insights Forecast, Growth, Trends 2024-2033

receptor blockers market going forward. Chronic kidney disease (CKD) is a long-term condition characterized by the gradual loss of kidney function over time. Angiotensin receptor blockers (ARBs) are used in the management of chronic kidney diseases (CKD) by lowering blood pressure, provide renal protection, to manage diabetic nephropathy, and in cardiovascular complications.

Make Your Report Purchase Here And Explore The Whole Industry's Data As Well:

<https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report>

Who Are the Leading Competitors in the Angiotensin Receptor Blockers (ARBs) Market Share?

Key players in the market include Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline PLC, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy's Laboratories Ltd., Takeda Pharmaceutical Company Limited, Movianto, Clinical Trial Logistics, Thermo Fisher Scientific, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, Abbvie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma.

Which Key Trends Are Driving [Angiotensin Receptor Blockers \(ARBs\) Market Growth](#)?

Major market players operating on angiotensin receptor blockers (ARBs) market are concentrating their efforts on creating innovative products and getting its approvals to strengthen their position in the market. Vericiguat is a medication used in the treatment of heart failure. It is a soluble guanylate cyclase (sGC) stimulator, and it is indicated to reduce the risk of cardiovascular death.

How Is The Global Angiotensin Receptor Blockers (ARBs) Market Segmented?

- 1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan
- 2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications
- 3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers

Geographical Insights: North America Leading The Angiotensin Receptor Blockers (ARBs) Market

North America was the largest region in the market in 2023. The regions covered in the report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Angiotensin Receptor Blockers (ARBs) Market Definition

Angiotensin receptor blockers (ARBs) are medications that dilate (widen) blood vessels and are used to treat conditions such as high blood pressure (hypertension), heart failure, and kidney disease in people with diabetes. Angiotensin is a chemical in the body that causes blood vessels to constrict. This constriction can raise the blood pressure and make the heart work harder.

[Angiotensin Receptor Blockers \(ARBs\) Global Market Report 2024](#) from TBRC covers the following information:

- Market size data for the forecast period: Historical and Future
- Macroeconomic factors affecting the market in the short and long run
- Analysis of the macro and micro economic factors that have affected the market in the past five years
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

An overview of the global angiotensin receptor blockers (ARBs) market report covering trends, opportunities, strategies, and more

The Angiotensin Receptor Blockers (ARBs) Global Market Report 2024 by [The Business Research Company](#) is the most comprehensive report that provides insights on angiotensin receptor blockers (ARBs) market size, angiotensin receptor blockers (ARBs) market drivers and trends, angiotensin receptor blockers (ARBs) market major players and angiotensin receptor blockers (ARBs) market growth across geographies. This report helps you gain in-depth insights into opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:

Convalescent Plasma Therapy Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/convalescent-plasma-therapy-global-market-report>

Mycoplasma Testing Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/mycoplasma-testing-global-market-report>

Patient Blood Management Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/patient-blood-management-global-market-report>

What Does The Business Research Company Do?

The Business Research Company publishes over 15,000 reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package, and much more.

Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/747381747>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.